T
Tscan Therapeutics Inc (TCRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$0.15
-0.02 (-9.65%)
Market Cap: $10.89M
Last updated: Nov 17, 2026 at 11:05 AM ET
Tscan Therapeutics Inc (TCRX) Valuation Multiples
Tscan Therapeutics (TCRX) trades at 3.6x sales and 0.5x book value. Its P/S of 3.6x is below its 5-year median of 12.7x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | N/A |
| Price to sales | 3.6x |
| Price to book | 0.5x |
| EV/FCF | 0.2x |
| PEG | N/A |
| FCF yield | -591.9% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 3.6x | 12.7x | N/A |
| P/B | 0.5x | 1.1x | N/A |
Valuation History
Over the 5 year ends shown, its P/S ranged from 1.9x in 2021 to 121.4x in 2024.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $1.00 | 12.6x | 1.1x |
| 2024 | $3.04 | 121.4x | 1.5x |
| 2023 | $5.83 | 12.6x | 3.7x |
| 2022 | $1.55 | 3.1x | 0.4x |
| 2021 | $4.50 | 1.9x | 0.7x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About TCRX
Is TCRX stock overvalued?
GNG's valuation label for TCRX is Undervalued.
What is TCRX's price to sales ratio?
Tscan Therapeutics has a price to sales ratio of 3.6x.
TCRX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors